IgA nephropathy: a review of existing and emerging therapies
IgA nephropathy (IgAN) is the most common form of primary glomerulonephritis worldwide. Recently, there have been multiple advances in the understanding of IgAN pathophysiology and therapeutic options. Despite the advent of new treatment options, individual risk stratification of the disease course...
Main Authors: | Sahibzadi Mahrukh Noor, Farah Abuazzam, Roy Mathew, Zhiwei Zhang, Amir Abdipour, Sayna Norouzi |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-05-01
|
Series: | Frontiers in Nephrology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fneph.2023.1175088/full |
Similar Items
-
Therapy of IgA nephropathy: time for a paradigm change
by: Jonathan Barratt, et al.
Published: (2024-08-01) -
Targeted-release budesonide: A comprehensive review on its potential in IgA nephropathy
by: Fei-fan Qi, et al.
Published: (2025-02-01) -
IgA Nephropathy: Current Treatment and New Insights
by: Dimitra Petrou, et al.
Published: (2023-06-01) -
Use of low-dose sulodexide in IgA nephropathy patients on renin–angiotensin system blockades
by: Byeong Yun Yang, et al.
Published: (2012-09-01) -
Management of IgA Nephropathy in Pediatric Patients
by: Sophie Schroda, et al.
Published: (2022-05-01)